CellWell record HH-76945
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes
Dayoung Yoon; Ji Won Lee; Byoung Chul Cho; Eun Joo Kang; Jung Sun Kim; Taekyu Lim; Seong Yoon Yi; Yu Jung Kim; Mi Sun Ahn; Young Saing Kim; Ji Hyun Park; Seungtaek Lim; Hyung Soon Park; Jang Ho Cho; Byunghyun Jang; Ji Yoon Lee; Jiwon Kim; Jisoo Hong; Harim Koo; Seok Chung; Sang Won Shin; Yeul Hong Kim; Jason K Sa; Yoon Ji Choi
2026
In plain language
Profiling 121 early-stage and 74 advanced EGFR-mutant lung cancers found MTOR, ATRX, STAG2, ABL1 and SPEN mutations enriched in advanced disease, and in 84 TKI-treated patients TP53, KIT and ALK mutations marked poor response.
- Evidence
- Emerging
Cite this record: https://thecellwell.org/studies/HH-76945
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.